Cargando…
BKM120 sensitizes glioblastoma to the PARP inhibitor rucaparib by suppressing homologous recombination repair
PARP inhibitors have been approved for the therapy of cancers with homologous recombination (HR) deficiency based on the concept of “synthetic lethality”. However, glioblastoma (GBM) patients have gained little benefit from PARP inhibitors due to a lack of BRCA mutations. Herein, we demonstrated tha...
Autores principales: | Zhang, Shaolu, Peng, Xin, Li, Xiaofei, Liu, Hongyan, Zhao, Baoquan, Elkabets, Moshe, Liu, Yao, Wang, Wei, Wang, Ran, Zhong, Yuxu, Kong, Dexin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8150626/ https://www.ncbi.nlm.nih.gov/pubmed/34039959 http://dx.doi.org/10.1038/s41419-021-03805-6 |
Ejemplares similares
-
Hydroxychloroquine synergizes with the PI3K inhibitor BKM120 to exhibit antitumor efficacy independent of autophagy
por: Peng, Xin, et al.
Publicado: (2021) -
Correction to: Hydroxychloroquine synergizes with the PI3K inhibitor BKM120 to exhibit antitumor efficacy independent of autophagy
por: Peng, Xin, et al.
Publicado: (2021) -
Stellettin B Sensitizes Glioblastoma to DNA‐Damaging Treatments by Suppressing PI3K‐Mediated Homologous Recombination Repair
por: Peng, Xin, et al.
Publicado: (2022) -
Stellettin B renders glioblastoma vulnerable to poly (ADP-ribose) polymerase inhibitors via suppressing homology-directed repair
por: Peng, Xin, et al.
Publicado: (2023) -
ZSTK474 Sensitizes Glioblastoma to Temozolomide by Blocking Homologous Recombination Repair
por: Jiao, Wenhui, et al.
Publicado: (2022)